Number of participants experiencing any serious adverse events · patients with osteoarthritis
It is very uncertain whether tramadol alone changes number of participants experiencing any serious adverse events compared with NSAIDs (very low certainty).
1 finding from 1 review
Number of participants experiencing any serious adverse events · patients with osteoarthritis
It is very uncertain whether tramadol alone changes number of participants experiencing any serious adverse events compared with other opioids (very low certainty).
1 finding from 1 review
Number of participants experiencing any serious adverse events · patients with osteoarthritis
1 finding from 1 review
Number of participants experiencing any serious adverse events · patients with osteoarthritis
The review found no eligible studies for this question.
1 finding from 1 review
Number of participants experiencing any serious adverse events · Patients with osteoarthritis of the knee or hip
Tramadol alone may leads to higher number of participants experiencing any serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
Number of participants experiencing any serious adverse events · patients with osteoarthritis of the ankle
1 finding from 1 review
Number of participants experiencing any serious adverse events · people with Alzheimer's disease
Vitamin E (capsules 2000 IU/day in two divided doses) showed no clear difference in adverse events Number of participants reporting ≥ 1 serious adverse… compared with placebo (moderate certainty).
1 finding from 1 review
Number of participants experiencing any serious adverse events · MCI
1 finding from 1 review
Adverse events (not including serious adverse events): number of participants · patients with chronic obstructive pulmonary disease
Fixed‐dose combination aclidinium/formoterol leads to lower adverse events (not including serious adverse events): number of… compared with formoterol (high certainty).
1 finding from 1 review
Adverse events (not including serious adverse events): number of participants · patients with chronic obstructive pulmonary disease
Fixed‐dose combination aclidinium/formoterol showed no clear difference in adverse events (not including serious adverse events): number of… compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events (not including serious adverse events): number of participants · patients with chronic obstructive pulmonary disease
Fixed‐dose combination aclidinium/formoterol showed no clear difference in adverse events (not including serious adverse events): number of… compared with aclidinium alone (moderate certainty).
1 finding from 1 review
Adverse events, including serious adverse events Assessed by: number of participants with ≥ 1 event · adults with relapsing–remitting multiple sclerosis
Alemtuzumab 12 mg showed no clear difference in adverse events, including serious events Assessed by: number of… compared with interferon beta‐1a (low certainty).
1 finding from 1 review
Adverse events, including serious adverse events Assessed by: number of participants with ≥ 1 event · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…
Alemtuzumab 24 mg showed no clear difference in adverse events, including serious adverse events Assessed by: number… compared with interferon beta‐1a (low certainty).
1 finding from 1 review
Adverse effects: at least one serious adverse event · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…
Palliative care showed no clear difference in serious adverse events Assessed by: number of participants… compared with usual care (low certainty).
1 finding from 1 review
Intervention not reported
Number of participants experiencing 1 or more serious adverse events at the end of the intervention period · cognitively healthy people in late life
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Number of participants experiencing 1 or more serious adverse events at the end of the intervention period · cognitively healthy people in late life
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events Number of participants who died or withdrew and were hospitalized as a result of adverse effects of treatment · patients with Raynaud's phenomenon
1 finding from 1 review
Quality of life Drug resistance/microbial sensitivity Serious adverse events Lung function Hospitalisations Adverse events/side effects Number of participants colonised with P aeruginosa · patients with chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life Drug resistance/microbial sensitivity Serious adverse events Lung function Hospitalisations Adverse events/side effects Number of participants colonised with P aeruginosa · patients with chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life Drug resistance/microbial sensitivity Serious adverse events Lung function Hospitalisations Adverse events/side effects Number of participants colonised with P aeruginosa · patients with chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found